# Ruxolitinib W/ Preop Chemo For Triple Negative Inflammatory Brca

> **NCT02041429** · PHASE1,PHASE2 · COMPLETED · sponsor: **Dana-Farber Cancer Institute** · enrollment: 20 (actual)

## Conditions studied

- Recurrent Breast Cancer
- Metastatic Breast Cancer

## Interventions

- **DRUG:** Ruxolitinib
- **DRUG:** Paclitaxel

## Key facts

- **NCT ID:** NCT02041429
- **Lead sponsor:** Dana-Farber Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-02
- **Primary completion:** 2016-05
- **Final completion:** 2021-01
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2021-04-21

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02041429

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02041429, "Ruxolitinib W/ Preop Chemo For Triple Negative Inflammatory Brca". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT02041429. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*